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Gene expression profiling has identified several po-
tentially useful gene signatures for predicting out-
come or for selecting targeted therapy. However,
these signatures have been developed in fresh or fro-
zen tissue, and there is a need to apply them to rou-
tinely processed samples. Here, we demonstrate the
feasibility of a potentially high-throughput methodol-
ogy combining automated in situ hybridization with
quantum dot-labeled oligonucleotide probes followed
by spectral imaging for the detection and subsequent
deconvolution of multiple signals. This method is
semiautomated and quantitative and can be applied to
formalin-fixed, paraffin-embedded tissues. We have
combined dual in situ hybridization with immunohis-
tochemistry, enabling simultaneous measurement
of gene expression and cell lineage determination.
The technique achieves levels of sensitivity and spec-
ificity sufficient for the potential application of
known expression signatures to biopsy specimens
in a semiquantitative way, and the semiautomated
nature of the method enables application to high-
throughput studies. (J Mol Diagn 2007, 9:20–29; DOI:
10.2353/jmoldx.2007.060119)
Gene expression profiling experiments have identified
several gene signatures as markers either of tumor cat-
egories with distinct behaviors or predictive of disease
progression and response to therapy.1,2 Application of
such signatures to individual patients in a clinical setting
holds great potential for improving diagnosis and prog-
nosis and for providing guidance for tailored molecular
therapy.1–4 The generation and use of such signatures in
routine clinical practice is presently limited by the need
for relatively large amounts of high-quality frozen material
for microarray gene expression profiling.2,5 In contrast,
nearly all clinical material is routinely formalin-fixed and
processed to paraffin,5 a practice that is likely to continue
for the foreseeable future, especially outside large aca-
demic centers. In addition, gene signatures have largely
been derived from tissue homogenates,2 although recent
studies have demonstrated the importance of localization
of the genes that make up these signatures not only to the
tumor cells but also to their neighbors, such as immune
and stromal cells.6 There is therefore a need for a generic
method for simultaneous visualization of multiple genes in
formalin-fixed, paraffin-embedded (FFPE) tissue, ideally
by an automated or semiautomated method to enable
clinical use and application to high-throughput studies
investigating spatial localization of microarray gene
signatures.
Currently, gene expression in tissues is determined by
immunohistochemistry (IHC) and in situ hybridization
(ISH). However, the use of IHC for mapping expression of
gene signatures in FFPE tissue is hampered because
antibodies effective in FFPE sections are not commonly
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available for most of the markers composing gene sig-
natures.7 In contrast, probes useful for RNA ISH can be
easily constructed for any gene, and in theory, clinical
use on FFPE samples could be a reliable method of in situ
gene expression detection, although it is methodologi-
cally long and complex.8–10 We currently obviate the
lengthy procedure times with the routine use of auto-
mated, high-throughput colorimetric RNA ISH.11
Fluorescence-based detection systems, which would
be ideal for visualization of multiple probes, are ham-
pered by low sensitivity (particularly for oligonucleotide
probes),8,9 high autofluorescence of paraffin-embedded
tissue,12,13 with low resultant signal-to-noise ratio, limited
numbers of fluorophores, and overlapping spectra,14
making deconvolution of multiple signals challenging.
Furthermore, fluorescence-based techniques are non-
permanent, fading with time,15–17 rendering them subop-
timal for a clinical test for which a permanent record is
best for clinical governance. Quantum dots (QDs) have
recently been used for bioimaging by immunofluores-
cence17 for molecule17,18 and cell labeling,19–21 and,
more recently, in human clinical material.22 These
fluorescent semiconductor nanocrystals possess ex-
tremely high fluorescence efficiency and photostability,
making them near-optimal for many fluorescent applica-
tions.15–19,21–25 In addition, whereas their excitation
wavelength is constant, their emission wavelength is
sharp, symmetrical, and tunable, dependent on diame-
ter, with the potential for multicolor staining.24 These;
properties suggest that QDs might be highly useful in
application to clinical specimens.
Simultaneous detection of multiple fluorescent signals
requires spectral deconvolution to resolve individual sig-
nals. Spectral imaging relies on generation of a complete
optical profile for each pixel in the image field from which
multiple spectral distributions can be reconstructed via a
least-squares fitting linear unmixing approach.26 The
spectral information in the acquired datasets can then be
used to discriminate between autofluorescence and true
fluorescent signal and between different fluorescent sig-
nals.19 Such methods could also be highly advantageous
in a clinical setting but have yet to be explored and their
utility tested in a wide range of tissues. We have demon-
strated use of QD-based ISH in human specimens using
manual techniques.
Here, we have combined high-throughput, automated
ISH, QD-labeling of DNA and RNA probes and spectral
imaging to produce a novel technique for ISH that can be
used to apply gene expression signatures to FFPE tissue
biopsies at diagnosis.
Materials and Methods
Tissues
Archival routinely processed (10%) formalin-fixed, paraf-
fin-embedded human glioma tissue was obtained with
Institutional Review Board approval from the archives of
the Department of Pathology, Brigham and Women’s
Hospital. Mouse lung was harvested at necropsy. Mice
were perfused with 4% paraformaldehyde and fixed in
the same fixative for 18 hours at 4°C before processing to
paraffin blocks.
Cell Culture
LNCaP human prostate cancer cells were grown to 70%
confluence in RPMI-1640 (StemCell Technologies, Van-
couver, BC, Canada) supplemented with 10% fetal bo-
vine serum (StemCell Technologies) and incubated at
37°C with 5% CO2. The cells were then washed three
times in phosphate-buffered saline (PBS) and grown in
charcoal-stripped serum for 24 hours before R1881 treat-
ment and 48 hours before harvesting. The cells were
treated with 10 nmol/L R1881 in 100% ethanol and har-
vested at 2, 9.5, and 24 hours. Total RNA was isolated for
quantitative reverse transcriptase-polymerase chain re-
action (RT-PCR) experiments from one-half of the treated
cells, whereas the rest were pelleted, formalin-fixed, and
paraffin-embedded. Cultured mouse fibroblast cells,
both wild type and cyclin E1-null,27 were a kind gift from
Dr. Yan Geng and Peter Sicinski (Dana-Farber Cancer
Institute).
Reagents
Oligonucleotide probes were high-performance liquid
chromotography-purified and biotin-TEG-, digoxigenin
(DIG)-, or thiol-modified at the 5 end (Eurogentec, Sera-
ing, Belgium). Amine-coated QDs (580 nm) (Evident
Technologies, Troy, NY) were used for Q-ISH in human
brain tissue. QD 605 and 655 streptavidin conjugates
(Quantum Dot Corporation, Hayward, CA) were used for
conjugation to oligonucleotide/riboprobes for Q-ISH (see
below) and QD 655 streptavidin conjugate for IHC. QD
525 anti-DIG antibody conjugates (Quantum Dot Corpo-
ration) were used for DIG-labeled riboprobe ISH. Anti-
bodies to mcc10 and CD34 (Abcam, Cambridge, MA)
were used for IHC.
Probe Design
Two approaches were used. The probe for cyclin E1
(NM_001238) was designed using a sequence from
ENSEMBL (http://www.ensembl.org). Generic sequences
from the Illumina Oligator database (San Diego, CA) were
used for mcc10 (NM_011681), mammalian achaete-scute
homolog 1 (ASCL1) (NM_004316), NKX2-2 (NM_002509),
and fatty acid synthase (FAS) (NM_000043). For all genes,
50-mer-long sequences with approximately 50% guanine
cytosine content were selected from these areas and spec-
ificity checked using BLAST (http://www.ncbi.nlm.nih.gov/
blast). Reverse complement sequences were then pre-
pared as oligonucleotide probes (Table 1). RNA probes
were transcribed in vitro from DNA templates flanked by
phage RNA polymerase promoters, as previously
described.11
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Probe Conjugation
Amine-coated QDs were coupled to probe using a stan-
dard protocol (Evident Technologies). In brief, 200
mmol/L N--maleimidopropionic acid and 0.1 mmol/L 5-
sulfhydryl-modified oligonucleotide were dissolved in 500
l of 1 PBS and incubated for 2 hours at room temper-
ature, followed by purification by centrifugation at 5000
g for 15 minutes to remove excess N--maleimidopropi-
onic acid. Seventy microliters of the purified N--male-
imidopropionic acid-oligo was then added to 270 l of
water, 50 l of 10 PBS, 100 l of amine coated QDs
(Evident Technologies), and 10 l of 1-ethyl-3-(3-dimeth-
ylaminopropyl) carbodiimide-hydrochloride (100 mg/ml),
followed by incubation at room temperature for 2 hours,
after which the reaction was quenched by addition of 500
l of 1 mol/L Tris (pH 7.4). The conjugated QDs were then
purified by centrifugation in a 100k Omega Nanosep filter
(Pall Life Sciences, Hampshire, UK) for 10 minutes at
10,000  g.
Direct probe conjugation of streptavidin-coated QDs
was performed in a QD-to-probe ratio of 1:2 by mixing
both in a centrifuge tube and incubating at room temper-
ature for 60 minutes. The resultant conjugate was volume
reduced with a 100k Omega Nanosep exclusion filter
(Pall Life Sciences).
In Situ Hybridization
Manual in Situ Hybridization
Manual in situ hybridization was performed using stan-
dard methods.11 Sections were hybridized with the
mcc10 riboprobe for 14 hours at 42°C and washed in
0.1 SSC three times for 20 minutes at 47°C. Digoxige-
nin-tailed oligonucleotide probe for cyclin E1 was hybrid-
ized at 37°C and washed at 42°C.
Semiautomated in Situ Hybridization
DIG-labeled riboprobe ISH using QDs were performed
using a Ventana Discovery XT instrument (Ventana Med-
ical Systems, Tucson, AZ). Seven-micrometer-thick tis-
sue sections were deparaffinized (standard xylene and
industrial methylated spirits) and fixed in 4% paraformal-
dehyde for 10 minutes. Tissues were then permeabilized
by incubation in 1 mg/ml pepsin in 0.1 mol/L HCl for 20
minutes at 37°C followed by denaturation at 70°C for 10
minutes before hybridization with DIG-labeled riboprobe
at 65°C for 6 hours. Washes after hybridization were
performed using 0.1 SSC at 75°C twice for 6 minutes
followed by PBS at room temperature for 5 minutes. After
hybridization, slides were incubated with QDs 605-con-
jugated anti-DIG antibody (Invitrogen, Carlsbad, CA) for
30 minutes and rinsed thereafter twice in PBS for 5 min-
utes. All tissue sections were coverslipped using 90%
(v/v) glycerol/PBS mounting solution.
Immunohistochemistry
IHC for CD34 was performed using a rat anti-mouse
anti-CD34 antibody (Abcam) with pressure cooker target
retrieval in citrate buffer for 2 minutes. Primary anti-CD34
antibody was applied at a dilution of 1:50 in PBS and
incubated at room temperature for 60 minutes, followed
by detection using a QD-labeled anti-rat IgG antibody
(Invitrogen) at a dilution of 1:100 for 30 minutes at room
temperature. IHC for mcc10 was performed as previously
described28 using a primary rabbit polyclonal antibody
against mcc10 (kindly provided by Dr. F.J. De Mayo,
Baylor College of Medicine, Houston, TX) at a dilution of
1:100; mcc10 expression is cell specific, being entirely
confined to the bronchiolar epithelium.28
Combined Immunohistochemistry and in Situ
Hybridization
ISH was performed on a Discovery Machine (Ventana
Medical Systems). In brief, paraffin slides were deparaf-
finized on the machine by heating to 75°C and rinsed with
EZ buffer. Slides were then fixed in 4% paraformaldehyde
for 10 minutes and digested in 0.5 mg/ml pepsin for 10
minutes at 37°C. DIG-labeled Mcc10 riboprobe (1:50)
and biotin-labeled pulmonary surfactant (PS) probe (1:
50) were diluted in hybridization buffer and added to the
slides. Slides were hybridized at 65°C for 6 hours. After
hybridization, slides were rinsed twice in 0.1 SSC buffer
at 75°C, each for 6 minutes. Detection of DIG-labeled
mCC10 probe and biotin-labeled PS probe and CD34
protein were performed manually. QD 605 anti-DIG (1:
100 for mCC10; Invitrogen) and streptavidin QD 525
(1:100 for PS; Invitrogen) and CD34 primary antibody
were diluted in PBS buffer and incubated for 1 hour at
room temperature. Slides were then rinsed in PBS twice
for 5 minutes and incubated with QD 655 anti-rat IgG
antibody. Slides were rinsed in phosphate-buffered
saline-Tween twice for 5 minutes and coverslipped with
Vectashied (Vector Laboratories, Burlingame, CA).
Table 1. cDNA Sequences of Probes Used in Study
Name Accession no. cDNA oligonucleotide probe sequence
ASCL1 NM_004316 5-TTTCAGCTGTGCGTGTTAGAGGTGATGGGAGTTACTATAACGCGTGTGCT-3
FAS NM_000043 5-AAAAACAAACACAGACAAACACCAAACATGGAGTTGGTGCCCGGCGCCGG-3
MCC10 NM_011681 5-ATAGACTCCAAATAAACCACATCTACAGACACCAAAGCCTCCAACCTCTA-3
Cyclin E1 NM_001238 5-ATCCTCGCTTTTCACAGTCTTGTCAATCTTGGCAATTTCTTCATCTGGGT-3
Nkx2.2 NM_00250 5-GGGCAGAGGGCTCCCTGCCTACAGGGTTTTCTTTTCCATATTTGAGAAAT-3
22 Byers et al
JMD February 2007, Vol. 9, No. 1
Spectral Imaging and Signal Quantitation
Using a Leitz Diaplan fluorescence microscope and a
CRI Nuance spectral analyzer (CRI Inc., Woburn, MA)
phosphate-buffered saline-Tween, image files were col-
lected at 5-nm wavelength intervals from 450 to 700 nm.
This system uses stacked liquid crystal filters to produce
a solid-state tunable Lyot filter. The image files, each
comprising the concatenated stack of images at each
wavelength interval per pixel, were then used to recon-
struct multiple spectral distributions via a maximum like-
lihood method. Specifically, the maximum likelihood dis-
tributions at each pixel were determined for spectral
distributions obtained from autofluorescence and for the
QDs used in a given experiment. These distributions
represent signal intensity at each pixel for the defined
spectra and were converted to composite pseudocolo-
rized images to visualize staining distribution and inten-
sity for each QD. The signal intensities in the resultant
images were compared numerically using IPLab software
(Scanalytics, MD), according to manufacturer’s
instructions.
All composite image files were collected from slides at
5-nm wavelength intervals from 450 to 720 nm, with an
exposure of 1 second per wavelength interval for 400
magnification and 0.5 second per wavelength for 200
magnification, using a CRI Nuance system and analyzed
using the spectra of autofluorescence and of the relevant
QD emission spectrum using spectral unmixing,26 dis-
closing signal distribution otherwise obscured by
autofluorescence. A long wavelength bypass filter allow-
ing transmission of all emission wavelengths above 450
nm was used, and spectral deconvolution was performed
digitally, according to manufacturer’s instructions, on the
resultant image stack.
Quantitative Image Analysis
FAS QD ISH images were taken from 500 to 700 nm at 5
nm with a 72.1-millisecond exposure time at 40 objec-
tive magnification. To avoid variations in staining due to
heterogeneous cell densities, five images of distinct cell
clusters were taken for each time point, and the mean
signal intensity was calculated. Image analysis was per-
formed using ImageJ (National Institutes of Health, Be-
thesda, MD). Mean pixel intensity of the 605-nm QD
(FAS) was computed after applying a threshold of 100 to
eliminate low-level background and bias due to differing
amounts of negative space.
RNA Extraction and Real-Time PCR
LNCAP frozen pellets from single plate were placed in
TRIzolR Reagent (Invitrogen), and total RNA was pre-
pared by the acid phenol method. Total RNA was quan-
tified by ND-1000 (NanoDrop Technologies, Wilmington,
DE). One microgram of total RNA was subjected to re-
verse transcription using the SuperScript III First-Strand
Synthesis System (Invitrogen) in a total volume of 20 l
according to the manufacturer’s instructions. FAS-spe-
cific primers and probe were ordered as ready-to-use
primer and probe mix (Assay on Demand, Gene Expres-
sion product, Hs00188012_m1; Applied Biosystems,
Foster City, CA). The FAS probe was labeled with the
FAM reporter at 5 end and the TAMRA quencher at 3
end. Human -glucoronidase (VIC/MGB Probe; Applied
Biosystems) was chosen as the endogenous control. In
the -glucoronidase probe labeled with 5-VIC, the 3
end quencher has been substituted by the minor groove
binder groups that provide a more efficient fluorescence
quenching, resulting in an increased sensitivity. Quanti-
tative PCR was performed using an ABI Prism 7500 Se-
quence Detection System (Applied Biosystems) in a
25-l final volume containing 2 l of cDNA and appropri-
ate concentrations of TaqMan Universal Master mix and
gene expression assays (Applied Biosystems) according
the manufacturer’s instructions. The reactions were per-
formed in two independent analyses, each in duplicate,
using MicroAmp Optical 96-well plates (Applied Biosys-
tems). During the PCR operation, the plate was first held
at 50°C for 2 minutes and then at 95°C for 10 minutes to
denature nucleic acid samples. The amplification pro-
cess was executed with a thermal cycle of 95°C for 15
seconds and 60°C for 1 minute for 40 cycles. A serial
dilution of LNCAP RNA, from 1 g through 1 ng of total
RNA, was analyzed to verify the sensitivity and efficiency
of the assays. No template controls and no reverse tran-
scriptase controls were performed in parallel to exclude
transcript nonspecific amplification. To determine the
quantity of FAS-specific transcripts present in treated
cells at different time points relative to untreated ones, the
comparative threshold (Ct) method (the 2Ct method)
(User Bulletin no. 2; Applied Biosystems) was used. The
FAS Ct values were first normalized by subtracting the
respective Ct value obtained from the -glucoronidase
control (Ct  Ct target  Ct control) to compensate for
variations in input RNA amounts. The concentration of
FAS-specific mRNA in treated cells relative to untreated
cells was calculated by subtracting the normalized Ct
values obtained for untreated cells from those obtained
from treated samples (Ct  Ct treated  Ct un-
treated), and the relative concentration was determined
(2Ct).
Results
Visualization of mRNA Targets by Single Label
Quantum Dot-Based in Situ Hybridization
As a first step, we assessed the feasibility of QD conju-
gation to oligonucleotide cDNA probes and the use of
QD-labeled oligonucleotide probes in ISH on paraffin-
embedded tissue (Q-ISH), using similar techniques to
those we had performed using nonradioactive probes in
automated, high-throughput ISH experiments.11 Probes
were either labeled by direct conjugation of QD to oligo-
nucleotide or by biotinylation followed by streptavidin-
oligonucleotide conjugation in vitro. First, efficient
probe-QD conjugation was verified by gel electrophore-
sis (Figure 1A). Next, we chose a probe that was tissue
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specific, specific cell type restricted, and abundantly
expressed to compare traditional ISH with that performed
with QD-labeled probes. The murine mcc10 gene, spe-
cifically expressed in the Clara cells of the bronchiolar
epithelium,28 was targeted in mouse lung. To first test the
effectiveness of the probe sequence, DIG-labeled anti-
sense mcc10 riboprobe was compared with a DIG-
labeled mcc10 antisense oligonucleotide probe. Both
Figure 1. Use of direct quantum dot oligonucleotide conjugates for in situ detection of mcc10 in mouse lung. A: i, Agarose gel (0.8%) electrophoresis showing
no migration of unconjugated streptavidin-coated QDs (lane 1) and a differential gel shift with increasing probe-to-QD ratio. The individual samples are, from
left to right, 605-nm streptavidin-coated QD alone (lane 1) followed by molar ratios of QDs to probe of 5:1; 1:1, and 1:10 (lanes 2 to 4). ii, Agarose gel (0.8%)
electrophoresis showing strongest migration of unconjugated amine coated QDs (lane 1) and reducing gel shift with increasing probe-to-QD ratio. The individual
samples are, from left to right, 580-nm amine coated QD alone (lane 1) followed by molar ratios of QDs to probe: 1:20, 1:10, 1:5, 1:2, 1:1, 2:1, and 5:1 (lanes
2 to 8). B: Formalin-fixed, paraffin-embedded mouse (H&E 20 shown in i) lung hybridized with DIG-labeled antisense mcc10 riboprobe (ii) showing
localization of signal to Clara cells located in the bronchiolar epithelium. Magnification, 20. iii, DIG-labeled mcc10 antisense oligonucleotide showing similar
expression distribution to that observed with the antisense mcc10 riboprobe. Magnification, 20. iv, 5-biotinylated mcc10 antisense oligonucleotide (sequence
the same as in iii) in mouse lung disclosed using a 605-nm streptavidin-coated QD, demonstrating strong signal and localization to the bronchiolar epithelium.
Magnification, 20. v, DIG-labeled antisense mcc10 riboprobe disclosed with a 655-nm QD, demonstrating high signal in the same distribution to that of the
QD-disclosed oligonucleotide probe (iv). Magnification, 20. vi, IHC for mcc10 disclosed with diaminobenzidine demonstrated strong cytoplasmic staining in
the same distribution to that seen with either riboprobes or oligonucleotide probes (ii–v). Magnification, 20. C: i, Formalin-fixed, paraffin-embedded wild-type
mouse fibroblasts hybridized with DIG-tailed antisense cyclin E1 oligonucleotide probe showing strong hybridization signal [4,6-diamidino-2-phenylindole (DAPI)
counterstained]. Magnification, 40. ii, Formalin-fixed, paraffin-embedded cyclin E1 knockout mouse fibroblasts hybridized with DIG-tailed antisense cyclin E1
oligonucleotide probe showing the absence of hybridization signal (DAPI counterstained); small amounts of particulate QD are present, but cytoplasmic signal
is absent. Magnification, 40.
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resulted in specific signal in the mouse bronchial epithe-
lium, albeit with the smaller oligonucleotide probe gener-
ated a weaker signal, as expected (Figure 1B, ii and iii).
When the same 50-mer-biotinylated oligonucleotide was
conjugated with a 605-nm QD, the same specific signal
was obtained (Figure 1B, iv). No signal was seen with
either scrambled or unrelated oligonucleotide controls
(data not shown). The QD-labeled mcc10 riboprobe gave
the same bronchiolar signal as the oligonucleotide (Fig-
ure 1B, v) and showed similar levels of intensity; IHC for
mcc10 demonstrated the same pattern of staining (Figure
1B, vi). In addition, we established feasibility of QD oli-
gonucleotide ISH using a 50-mer 5 digoxigenin-tailed
probe for cyclin E1 in formalin-fixed, paraffin-embedded
pellets of mouse fibroblasts, either wild type or null/
knockout for cyclin E1, demonstrating strong hybridiza-
tion signal in the wild type and the absence of signal in
the knockout cells (Figure 1C).
Gene Signatures from Expression Profiling Data
Can Be Detected in Tumor Tissue by Quantum
Dot-Based in Situ Hybridization
To determine whether the technique could be an effective
tool in application to a published expression data set, we
identified and tested transcription factors ASCL1 and the
homeobox-containing gene NKX2-2, which have been
recently reported as members of an expression signature
Figure 2. Spectral analysis of quantum dot-based in situ hybridization to
resolve signal against tissue autofluorescence in routinely processed human
clinical tissue. i: H&E-stained human glioma is marked by the asterisk, and
the arrow points to the tumor normal brain interface. All tissue was routinely
formalin fixed, paraffin embedded, and imaged at20 magnification. ii: Raw
(real color) image of a human glioma with adjacent normal cerebral tissue,
hybridized with a 5 thiol-labeled antisense ASCL1 oligonucleotide probe/
amine-coated 580-nm QD conjugate, showing poor signal resolution due to
high green autofluorescence of brain tissue. iii and iv: Pseudocolorized
images following spectral analysis of image in ii showing signal for ASCL1
(iii) and NKX2-2 (iv) in red and tissue autofluorescence in green, demon-
strating ability of spectral imager to resolve hybridization signal against high
levels of inherent tissue autofluorescence.
Figure 3. Quantum dot-based in situ hybridization is photostable and quantifiable. A: Signal intensity for same slide of mouse lung hybridized with
DIG-labeled antisense mcc10 riboprobe visualized twice over an 18-month interval, demonstrating stability of QD fluorescence. There was no significant
loss of intensity between the first (ii) and second (iii) visualizations. H&E-stained section shown in i. Magnification, 40. B: FAS hybridization in 30-year
benign (i) and malignant (ii) prostatic core biopsies in a tissue microarray demonstrating low signal in benign tissue (iii) and high signal in prostatic
adenocarcinoma (iv). QD-disclosed IHC (605 nm) for FAS is shown for benign (v) and malignant (vi) prostatic tissue. Magnification, 20. Signal intensity
was determined by spectral analysis over nine benign (N) and 12 malignant (T) cores (vii) and measured using IPLab, demonstrating higher expression
of FAS in the malignant cores.
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set associated with poor prognosis in malignant glio-
mas.29 Analysis of their expression in two human gliomas
using the Q-ISH technique demonstrated abundant ex-
pression of both markers in the majority of glioma cells
with absent or low-level expression in the normal white
matter adjacent to the tumor (Figure 2) similar to results
seen by immunohistochemistry (data not shown).
Quantum Dot-Based in Situ Hybridization Is
Photostable, Quantitative, and Reproducible
To demonstrate that the system is durable, quantitative,
and reproducible, sections hybridized with mcc10 were
analyzed twice at an interval of 18 months, during which
time there was no significant reduction in signal intensity
(Figure 3A), in contrast to conventional fluorochromes,
which are subject to fading over time. Such stability is an
important property for use in clinical diagnostics. To test
stability of RNA in FFPE using this method, FAS expres-
sion was assayed using a directly conjugated oligonu-
cleotide DNA probe in a tissue microarray comprising
30-year-old FFPE benign and malignant prostatic needle
cores (Figure 3B, i and ii). Spectral analysis was again
used to resolve the hybridization signal from autofluores-
cence in each core (Figure 3B, iii and iv). After this, the
resultant image files were analyzed using IPLab (Scana-
lytics), a proprietary image analysis software package
enabling quantitation of image intensity, demonstrating
higher expression of FAS in the malignant cores com-
pared with adjacent normal tissue (Figure 3B, vii) and the
ability of the method to quantitate expression differences
between samples. This is of particular importance for
analysis of microarray identified gene signatures and was
capable of quantitation from 10 to nearly 2000 (arbitrary
units), demonstrating a wide dynamic range. In addition,
fluorescence provides a linear relationship between the
amount of probe hybridized and signal intensity not seen
with chromogenic methods and is critically important for
accurate measurement of relative expression levels. Be-
cause oligonucleotides are used and the number of mod-
ified nucleotides with attached QDs is identical for each
probe, signal intensity is directly proportional to the
amount of hybridization present and therefore more pre-
cisely representative of the transcript level in the tissue
than nonfluorescent methods.
To directly address quantitation, we compared the
signal intensity as determined by quantitative spectral
imaging to RT-PCR. To do this, LNCAP cells were grown
in charcoal-stripped serum, which was subsequently
stimulated with the synthetic androgen R1881, and har-
vested at the times shown in Figure 4. The androgen-
regulated gene FAS was evaluated at the transcript level
by quantitative RT-PCR on RNA obtained from these cells
at time 0 and at various time points and compared with
expression levels of FAS as determined by quantitation of
spectral images of the same cells, at the same time
points, hybridized to FAS after paraffin embedding. FAS
mRNA expression as determined by quantitation of fluo-
rescence in tissue sections hybridized with the FAS
probe correlated to transcript levels in the same cells
determined by quantitative RT-PCR.
Deconvolution by Spectral Imaging
In each of the above experiments, spectral imaging was
used to resolve hybridization signal from tissue autofluo-
rescence (Figures 2 and 3B). In brief, composite image
files were collected from the slides at 5-nm wavelength
intervals from 450 to 720 nm using a CRI Nuance system
and analyzed using the spectra of autofluorescence and
of the relevant QD emission spectrum using spectral
unmixing,25 disclosing signal distribution otherwise ob-
scured by autofluorescence (Figure 2).
Multiplex Quantum Dot-Based in Situ
Hybridization Is Feasible
Use of QDs for signal disclosure opens the possibility of
multiplex detection based on the ability to use QDs with
different emission wavelengths.30 Therefore, we next at-
tempted to separate multiple fluorescent signals by spec-
tral deconvolution. Aliquots of QDs were placed on glass
slides and coverslipped, and spectral profiles were cap-
tured for QDs at each wavelength of emission. The spec-
tral profile of tissue autofluorescence was captured sep-
arately, and these profiles were used in a least-squares
fitting algorithm to reconstruct autofluorescent and QD
fluorescent images.
We then performed ISH using a semiautomated sys-
tem, because a manual technique is likely to be cumber-
some for routine clinical use. Using this semiautomated
system, we performed simultaneous riboprobe-ISH for
mcc10 and PS disclosed by two different color QDs, both
separately and in duplex, and analyzed composite im-
ages. Specifically, image stacks were captured, using
the spectral analyzer, from sections hybridized simulta-
neously with a riboprobe to mcc10 and a riboprobe to PS.
PS was expressed in both the bronchiolar epithelium and
alveolar pneumocytes (Figure 5A, i–v), whereas mcc10
was localized only to the bronchiolar epithelium (Figure
5A, vi–x). Q-ISH for mcc10 and PS were then performed
with simultaneous hybridization of a biotinylated mcc10
riboprobe and a DIG-labeled PS riboprobe combined
with simultaneous IHC for CD34 (Figure 5B, i). The mcc10
probe was disclosed using streptavidin-coated QDs (605
nm), the PS probe using an anti-DIG antibody directly
conjugated to QDs (525 nm), and CD34 antibody staining
with a 655-nm QD-conjugated secondary antibody. The
signals for mcc10, PS, and CD34 were resolved using
spectral deconvolution, demonstrating surfactant expres-
sion in type 2 pneumocytes as well as in a subset of Clara
cells (Figure 5B, ii), CD34 in alveolar capillaries (Figure
4B, iii), and mcc10 expression in Clara cells (Figure 5B,
iv). The resultant triplex signal detection and deconvolu-
tion are shown in Figure 5B, v.
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Discussion
The results demonstrate successful generation and
use of QD-labeled oligonucleotide and RNA probes
for FFPE ISH. This enabled simultaneous detection of
multiple mRNA targets by multiplex Q-ISH on FFPE, with
deconvolution of individual hybridization signals using
quantitative spectral imaging. In addition, multiplex Q-
ISH was adapted for semiautomated use. Taken to-
gether, these features will enable multiplex in situ tran-
script detection and quantification in routinely processed
human clinical tissue, facilitating translation of gene ex-
pression signatures to diagnostic material, potentially in
high throughput.
QDs are a novel class of inorganic fluorophores, with
near ideal fluorescence properties, that have been used
to improve signal detection in immunofluorescence.17
They have been used in detection of FISH after hybrid-
ization for 1q1230 and HER2,17 and their use for simulta-
neous detection of up to two genes has been reported in
fresh animal and tissue culture material.31 However, the
vast majority of clinical tissue is in the form of formalin-
fixed material, and there is therefore a need for applica-
tion of QDs to such material, not only for analysis of
prospective clinical material in a routine diagnostic set-
ting but also for analysis of the existing archive of paraf-
fin-embedded tissue. We have very recently demon-
strated use of QD-based ISH in clinical material22 but
only in a manual system and only in hemopoietic tissues.
To be useful clinically, however, a method must be ca-
pable of automation and applicable to all types of tissues.
To overcome this limitation of existing methods for clinical
use, we have combined high-throughput automated ISH,
QD-labeling of DNA and RNA probes, and spectral im-
aging to produce a novel technique for ISH to enable
multiplex mRNA transcript detection in FFPE tissue of
both murine and human origin. Specifically, we have
combined the extremely high fluorescence of QDs with
spectral imaging both to remove autofluorescence digi-
tally, thereby improving signal-to-noise ratio and effec-
tively increasing the sensitivity of the probes used, and to
resolve multiple signals in the same tissue section. Im-
portantly for clinical studies, the method used is applica-
ble to paraffin-embedded tissue sections, for which
autofluorescence is a particular problem.12,13 The spec-
tral imager also enables quantitation of signal intensity,
which is necessary for analysis of microarray-identified
genes, many of which show relatively low fold changes in
expression level between different groups.1,2 The
method described allows precise measurement of signal
intensity within the reconstructed images, whereas the
Figure 4. Quantum dot-based in situ hybridization is quantitative. The signal
intensity as determined by quantitative spectral imaging (A: magnification,
40) was compared with that obtained from the same cells by RT-PCR.
LNCaP cells were grown in charcoal-stripped serum and subsequently stim-
ulated with the synthetic androgen R1881 and harvested at 2, 9.5, and 24
hours. Transcript levels of the androgen-regulated gene FAS were evaluated
both at the tissue level and by quantitative RT-PCR. Quantitation of FAS
mRNA by spectral images of FFPE LNCaP cells (A and B) was highly
correlated with FAS mRNA expression as determined by quantitation of
transcript by quantitative RT-PCR (C and D).
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linear relationship between probe hybridization and fluo-
rescence also enables semiquantitation by the method
described.
The use of QDs for biological imaging was first dem-
onstrated by Wu et al,17 who reported their use for anti-
body detection of HER2. Several reports have under-
scored their use for protein detection,32 but there have
been relatively few reports of their use for detection of in
situ hybridization,22,31–35 reflecting the technical difficulty
of this endeavor. The specific technical hurdles to their
use in ISH, which were also faced and overcome in the
present work, include optimization of QD/oligonucleotide
conjugation, signal stability (particularly with older
sources of QD), tissue autofluorescence (a particular
problem in their use in clinical material), and quantitation
of signal. The last two are of particular importance in
clinical samples and also hamper interpretation of opti-
mization experiments, especially those directed at opti-
mizing tissue permeabilization and conjugation ratio. The
use of spectral imaging was critical in overcoming these
hurdles.
We have demonstrated use of QD labeling and semi-
quantitative detection of multiplex ISH in routinely pro-
cessed clinical tissue samples and laid the groundwork
for using this methodology to validate gene expression
microarray data. Spectral imaging has been used to re-
construct multiple spectral components from the result-
ant composite images, enabling sensitive colocalization
of multiple genes, whereas use of fluorescence facilitates
quantitation. Importantly, the semiautomated nature of
the method will facilitate translational application of mi-
croarray-identified gene signatures to clinical research
and diagnostics, whereas the ability of spectral imaging
to resolve multiple signals offers the possibility of multi-
plexed probe detection.
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